The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of ADHD in neurofibromatosis type 1
Open accessAbstract
Forty-six of 93 children with neurofibromatosis type 1 (NF1) were found to satisfy the diagnostic criteria for attention-deficit-hyperactivity disorder (ADHD). Detailed comparisons were made among 20 children with NF1 and ADHD (12 males, 8 females; mean age 10.7 years, SD 2.2), 26 control children with NF1 (15 males, 11 females; mean age 11.3 years, SD 2.3), 14 control children with ADHD (7 males; mean age 9.9 years, SD 1.9), and 14 normally developing control children (7 males; mean age 11.2 years, SD 2.8). Children with NF1 and ADHD had the lowest IQ scores among the four groups. Test of Variables of Attention (TOVA) scores were poorer in the NF1-ADHD and ADHD control groups than in the two non-ADHD groups. Those with NF1 and ADHD were rated significantly poorer on the Child Behavior Checklist (CBCL) than were the NF1 control group. By administrating low doses (5 to 15 mg) of methylphenidate to the NF1-ADHD group, significantly improved TOVA scores were obtained. One-year follow-up yielded significantly improved CBCL scores. Our results show a high incidence of ADHD in NF1 and support an association between ADHD and learning and social problems in children with NF1. It was demonstrated that stimulant medication can lead to improvement in cognitive, academic, and social problems of children with NF1 and ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methylphenidate Dosing: Twice Daily Versus Three Times Daily
Stein, M. A., Blondis, T. A., Schnitzler, E. R., O'Brien, T., Fishkin, J., Blackwell, B., Szumowski, E., & Roizen, N. J. (1996) · Pediatrics · doi:10.1542/peds.98.4.748 · Cited by 151 · cited 1×
“The test has established normative values (Greenberg and Waldman 1994), has demonstrated reliability (Leark 2000, Llorente 2000), validity (Forbes 1998), and has been used in treatment efficacy studies (Stein et al. 1996, Semrud-Clikeman and Wical 1999).”
Method
Cited by
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045906 · Cited by 1,053
Neurofibromatosis Type 1 Revisited
Williams, V. C., Lucas, J., Babcock, M. A., Gutmann, D. H., Korf, B., & Maria, B. L. (2009) · Pediatrics · doi:10.1542/peds.2007-3204 · Cited by 695
The nature and frequency of cognitive deficits in children with neurofibromatosis type 1
Hyman, S. L., Shores, A., & North, K. N. (2005) · Neurology · doi:10.1212/01.wnl.0000179303.72345.ce · Cited by 637
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
Li, W., Cui, Y., Kushner, S. A., Brown, R. A. M., Jentsch, J. D., Frankland, P. W., Cannon, T. D., & Silva, A. J. (2005) · Current Biology · doi:10.1016/j.cub.2005.09.043 · Cited by 402
Metadata
- Authors
- Mautner, V.-F., Kluwe, L., Thakker, S. D., & Leark, R. A.
- Venue
- Developmental Medicine and Child Neurology
- Publisher
- Wiley
- Published
- 2002-03-25
- Volume
- 44
- Issue
- 03
- Pages
- 164
- ISSN
- 0012-1622 (ISSN-L)
- 1469-8749
- OpenAlex
- W4230624474
- Cited by
- 249
- References
- 1
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of ADHD in neurofibromatosis type 1. https://app.cochat.ai/papers/10.1017/s0012162201001876
- The paper
- Mautner, V.-F., Kluwe, L., Thakker, S. D., & Leark, R. A. (2002). Treatment of ADHD in neurofibromatosis type 1. Developmental Medicine and Child Neurology. https://doi.org/10.1017/s0012162201001876
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.